Michael Hunt, CFO of ReNeuron Group (RENE) (LSE:RENE) will be giving a briefing at the Shares Investor Evening on 27th October 2016. It will take place in London at an investor evening being organised by Shares magazine; the event is supported by AJ Bell Youinvest.
ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. The Company’s therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development.
ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.
The Shares event offers a unique opportunity to hear about the latest plans and strategy from the Directors of UK listed companies and Fund Managers, attendees can personally put forward questions to the presenters. The event will take place at the Novotel Tower Bridge, 10 Pepys Street, London EC3N 2NR. Registration begins at 18.00 and presentations at 18.30, followed by a drinks reception where attendees can mingle with the speakers and fellow investors.
Companies presenting at the event include:
Berkeley Energia (BKY)
ReNeuron Group (RENE)
Sphere Medical (SPHR)
+ more to be announced
Investors can register now for free at: https://www.sharesmagazine.co.uk/events
At 11:07am: (LON:RENE) ReNeuron Group PLC share price was 0p at 2.5p
Story provided by StockMarketWire.com